DYNLT1 gene expression is downregulated in whole blood of patients at different Huntington’s disease stages

Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG nucleotide expansion, which encodes the amino acid glutamine, in the huntingtin gene. HD is characterized by motor, cognitive, and psychiatric dysfunctions. In a previous study, we showed by qPCR that some genes altered in an...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences 2021-05, Vol.42 (5), p.1963-1967
Main Authors: Rosseto, S. M., Alarcon, T. A., Rocha, D. M. C., Ribeiro, F. M., Ferguson, S. S. G., Martins-Silva, C., Muniz, M. R., Costa, P. F., Guimarães, D. A., Pires, Rita G. W.
Format: Article
Language:English
Subjects:
Animals
Blood
Case-Control Studies
Cognitive ability
Disease Models, Animal
Disease Progression
Dynein
Dyneins - blood
Dyneins - genetics
Gene Expression
Glutamine
Humans
Huntingtin
Huntingtin Protein - genetics
Huntington Disease - genetics
Huntington's disease
Huntingtons disease
Medicine
Medicine & Public Health
Mice
Neurodegenerative diseases
Neurology
Neuroradiology
Neurosciences
Neurosurgery
Original Article
Polyglutamine
Psychiatry
Trinucleotide repeats
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG nucleotide expansion, which encodes the amino acid glutamine, in the huntingtin gene. HD is characterized by motor, cognitive, and psychiatric dysfunctions. In a previous study, we showed by qPCR that some genes altered in an HD mouse model were also altered in blood of HD patients. These alterations were mainly with respect to the dynein family. Therefore, this study aimed to investigate whether dynein light chain Tctex type 1 ( DYNLT1 ) is altered in HD patients and if there is a correlation between DYNLT1 gene expression changes and disease progression. We assessed the DYNLT1 gene expression in the blood of 19 HD patients and 20 healthy age-matched controls. Also, in 6 of these patients, we analyzed the DYNLT1 expression at two time points, 3 years apart. The DYNLT1 gene expression in the whole blood of HD patients was significantly downregulated and this difference was widened in later stages. These data suggest that DYNLT1 could emerge as a peripheral prognostic indicator in HD and, also, might be a target for potential intervention in the future.
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-020-04772-0